InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,129.60
(
-0.24%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.16
(
-0.37%
)
Bitcoin
60,853.15
(
0.07%
)
Post# of 462568
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

abew4me

Send PM Follow Ignore
Followers 43
Posts 4891
Boards Moderated 0
Alias Born 04/30/2005

abew4me

Re: Investor2014 post# 427234

Monday, 08/14/2023 2:30:41 PM

Monday, August 14, 2023 2:30:41 PM

Post# of 462568
Yes it most certainly is.

Once A2-73 has obtained FDA approval for Rett, that is the disease the FDA has assigned to that drug.

Therefore, if Anavex plans to submit an NDA using A2-73 for Fragile X (or any other disease) without conducting a P1 or P2, then they are in fact repurposing that drug.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News
InvestorsHub NewsWire

FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM

Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM

Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM

Start posting your company's news
Only $200 per official company press release!